Insider Transactions in Q2 2025 at Ultragenyx Pharmaceutical Inc. (RARE)
Insider Transaction List (Q2 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 15
2025
|
Amrit Ray |
BUY
Grant, award, or other acquisition
|
Direct |
5,740
+19.72%
|
-
|
|
May 15
2025
|
Deborah Dunsire |
BUY
Grant, award, or other acquisition
|
Direct |
5,740
+15.7%
|
-
|
|
May 15
2025
|
Matthew K Fust |
BUY
Grant, award, or other acquisition
|
Direct |
5,740
+18.12%
|
-
|
|
May 15
2025
|
Michael Narachi |
BUY
Grant, award, or other acquisition
|
Direct |
5,740
+14.94%
|
-
|
|
May 15
2025
|
Corazon (Corsee) D. Sanders |
BUY
Grant, award, or other acquisition
|
Direct |
5,740
+24.44%
|
-
|
|
May 15
2025
|
Daniel G Welch |
BUY
Grant, award, or other acquisition
|
Direct |
5,740
+14.94%
|
-
|
|
May 15
2025
|
Shehnaaz Suliman |
BUY
Grant, award, or other acquisition
|
Direct |
5,740
+18.12%
|
-
|
|
May 05
2025
|
Eric Crombez EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
520
-0.72%
|
$20,280
$39.24 P/Share
|
|
Apr 21
2025
|
Eric Crombez EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
242
-0.34%
|
$8,470
$35.11 P/Share
|